It showed the patient to be an extensive metabolizer of beta blocking
agents, with both alleles of the wild type, so poor metabolism and abnormal pharmacokinetics could not explain the occurrence of hyperkalemia in this patient.
Groundbreaking clinical trial results have demonstrated that long-term treatment with the beta blocking
agent carvedilol following a heart attack can reduce the risk of patients having another heart attack by 41 percent and dying by 23 percent.
New data from the COPERNICUS (CarvedilOl ProspEctive RaNdomIzed CUmulative Survival) trial presented Monday at the American Heart Association's 73rd Annual Scientific Sessions showed that the beta blocking
agent Coreg(R) reduced the risk of death or hospitalization due to heart failure by nearly a third in patients with advanced stages of the disease who were already taking ACE-based therapy.